18:09 , Feb 15, 2019 |  BC Week In Review  |  Company News

Sanofi, Regeneron cut Praluent list price by 60%

Sanofi (Euronext:SAN; NASDAQ:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are dropping the list price of PCSK9 inhibitor Praluent alirocumab by 60% to match the $5,850 annual price of competitor LDL-C lowering drug Repatha evolocumab. Last year,...
23:45 , Feb 13, 2019 |  BC Extra  |  Company News

Teva down after predicting a 'trough' year ahead

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) lost $1.49 to $17.63 on NYSE Wednesday when the company reported a decrease in 4Q18 generics sales and introduced 2019 guidance that was lower than the Street had...
22:40 , Feb 11, 2019 |  BC Extra  |  Company News

Sanofi, Regeneron cut Praluent list price by 60%

Sanofi (Euronext:SAN; NASDAQ:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are dropping the list price of PCSK9 inhibitor Praluent alirocumab by 60% to match the $5,850 annual price of competitor LDL-C lowering drug Repatha evolocumab. Last year,...
05:01 , Feb 5, 2019 |  BC Extra  |  Financial News

Real-world analytics company Aetion tops off series B

Aetion Inc. (New York, N.Y.) raised an additional $27 million in its series B round Tuesday to continue building its real-world evidence analytics platform. New investors Sanofi (Euronext:SAN; NASDAQ:SNY), UCB S.A. (Euronext:UCB), McKesson Ventures and...
20:04 , Feb 4, 2019 |  BC Extra  |  Company News

Management tracks: PhRMA, Amgen, Apellis

Sanofi (NASDAQ:SNY; Euronext:SAN) CEO Olivier Brandicourt became chairman of PhRMA. Brandicourt was chairman-elect and succeeds Robert Bradway, who is chairman and CEO of Amgen Inc. (NASDAQ:AMGN). PhRMA named Giovanni Caforio chairman-elect. Caforio is chairman and...
01:09 , Feb 1, 2019 |  BC Week In Review  |  Company News

Report: five companies would take brunt of Trump Part B proposal

The cost of an international reference pricing scheme the Trump administration has proposed for Medicare Part B would fall most heavily on five companies: Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Amgen Inc. (NASDAQ:AMGN), Bristol-Myers Squibb Co. (NYSE:BMY),...
23:01 , Jan 31, 2019 |  BC Extra  |  Company News

Management tracks: Calico, Apellis, Immutep

Calico Life Sciences LLC (South San Francisco, Calif.) hired Aarif Khakoo as its first head of drug development. He will lead the company’s early stage development from candidate selection through Phase II. Khakoo was VP...
00:04 , Jan 31, 2019 |  BC Extra  |  Politics & Policy

Report: five companies would take brunt of Trump Part B proposal

The cost of an international reference pricing scheme the Trump administration has proposed for Medicare Part B would fall most heavily on five companies: Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Amgen Inc. (NASDAQ:AMGN), Bristol-Myers Squibb Co. (NYSE:BMY),...
00:27 , Jan 30, 2019 |  BC Extra  |  Company News

Amgen's guidance comes up short, but migraine drug sales show promise

Amgen Inc. (NASDAQ:AMGN) reported 4Q18 and 2018 earnings that beat consensus estimates on Tuesday but the bellwether’s 2019 guidance fell shy of analyst expectations. The company said it expects 2019 non-GAAP EPS of $13.10-$14.30, below...
21:42 , Jan 25, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 15 profitable biotechs and pharmas are slated to report earnings this week. (A) Before U.S. markets open; during trading hours in Europe; (B) Six-month EPS estimate; (C) Fiscal 3Q; (D)...